What determines long-term outcomes using fully bioresorbable scaffolds - the device, the operator or the lesion?
Consult the latest EuroIntervention article on Bioresorbable scaffolds by K. Yamaji, L. Räber, and S. Windecker
In the year of its 40 anniversary, percutaneous coronary intervention (PCI) has evolved from balloon angioplasty over bare metal stents to drug-eluting stents (DES) and has, more recently, witnessed the advent of fully bioresorbable scaffolds (BRS). New-generation DES constitute the current benchmark in PCI and are indicated in all patient and lesion subsets, with excellent early (one-year rate of stent thrombosis and late outcomes. Indeed, PCI has matured into the most frequently performed revascularisation procedure due to its life-saving performance among patients presenting with acute coronary syndromes, as well as rivalling outcomes compared with coronary artery bypass surgery among patients with multivessel coronary artery disease, including left main disease. Find out more...
Kyohei Yamaji, MD, PhD; Lorenz Räber, MD, PhD; Stephan Windecker*, MD
Department of Cardiology, Bern University Hospital, Bern, Switzerland